In 2019, a new AMR accelerator kicked off under the aegis of the Innovative Medicines Initiative as a follow-up and evolutive next step to the former New Drugs for Bad Bugs programme. European Biotechnology spoke with Rob Stavenger, its coordinator at GlaxoSmithKline, about the goals of the €295m initiative, its cooperation with SMEs, and the relevance of push and pull incentives in the field.
Sherlock Bioscience and Mologic enter partnership
Latest NewsSynbio specialist Sherlock Biosciences and next-generation lateral flow testing expert Mologic Ltd have joined forces to develop a no-instrument rapid testing platform detecting virtually every infectious pathogen in low resource settings.
Protein protects against liver fibrosis
Latest NewsGerman researchers have shown that a protein protects against the development of liver fibrosis by shutting down inflammatory signalling in liver stellate cells of the liver.
bit bio restarts with new management
Latest NewsCell reprogramming specialist bit bio has expanded its management with renowned experts in the field.
BioVersys receives up to €8m from CARB-X
Latest NewsSwiss biotech company BioVersys AG has received a €8m grant by US-based non-profit organisation CARB-X to develop novel anti-virulence antibiotics to treat severe bacterial infections.
Recipharm founder to lead Amarna board
AppointmentsAmarna Therapeutics has appointed a new Supervisory Board, led by healthcare and biotech pioneer Thomas Eldered.
Researchers identify viral inflammation switch
Latest NewsA team of Japanese and German researchers has found the protein that helps activate the inflammasome following viral invasion.
EIT Innovator Award: Marc Julien awarded
AppointmentsDiabeloop CEO Marc Julien has won the EIT Innovators Award.
Rotavirus vaccines kill cancer cells
Latest NewsResearchers at University Lyon have found a potential repurposing application of two market-approved rotavirus vaccines.
Polyphor presents AMR breaker
Latest NewsSwiss Polyphor AG and researchers from the University of Zurich have presented the mechanism of action of a new class of antibiotics.
IMI AMR Accelerator: Allow the few to make the most of their resources
OpinionIn 2019, a new AMR accelerator kicked off under the aegis of the Innovative Medicines Initiative as a follow-up and evolutive next step to the former New Drugs for Bad Bugs programme. European Biotechnology spoke with Rob Stavenger, its coordinator at GlaxoSmithKline, about the goals of the €295m initiative, its cooperation with SMEs, and the relevance of push and pull incentives in the field.